BioBusiness 2008

Next February WBR is host to pharma’s premier and most exclusive global biopartnering event, BioBusiness 2008. Designed especially for pharma companies looking to in-license or partner and small biotechs requiring funding, out-licensing or partners, the event has something for everyone.

The full 3-day schedule offers a mix of 1-2-1 partnering meetings, in-depth presentations and deal case studies, informal roundtable discussion groups and the opportunity to network with many senior-level executives, directors and CEOs. The event has a unique 50/50 pharma-biotech split and is almost exclusively focused on business development and licensing, making it the conference of choice for deal-makers.

As soon as you register for the event, you will be issued with a special password to access the state-of-the-art online partnering system. This allows you to plan your event schedule by allowing you to pre-arrange meetings with senior conference delegates.

New for 2008:

Inflammation & CNS focus day – CNS is the second largest therapeutic area in the market, and the fastest growing. This focus day will give you unique insight from experts in the area both from an R&D and BD&L perspective, with headline deals and breakthrough science showcased.

Therapeutic stream – In the main conference itself, benefit from a whole stream dedicated to giving you critical insights into the hottest therapeutic areas. Leading experts from oncology, metabolic diseases, biomarkers, vaccines and RNAi will give an overview of the business and scientific issues which are shaping these areas.

Legal contracts – A team of legal experts will pull apart a mock contract to uncover the most tricky clauses in any deal contract and show you how best to deal with them. Giving you the essential knowledge you need to navigate your way through negotiations and deal situations, you will have the chance to address the panel with your own experiences and questions.

Upfront payments vs. royalties – Join the debate with a broad range of industry experts on finding the optimum combination of upfront payments, royalties and milestones. How far does your partner affect your decision? What is the right fit for your own organisation? What should you do to ensure growth and develop your own R&D?

There will also be a stronger than ever focus on dissecting the biggest and most creative deals of the last 12 months, with the following deals presented during the 3 days:

Novartis/Intercell
GSK/EPIX
Wyeth/Pharmacopeia
Boehringer Ingelheim/Wyeth
Genzyme/AnorMED
Roche/Transgene
Bayer/Onyx
Bristol-Myers Squibb/AstraZeneca
Pfizer/Icagen

To register for this event or for full details, please visit the Biobusiness website at http://www.wbr.co.uk/biobusiness08/

To make any comments on this article, or to ask a question of the author, please contact the publisher. If you would like to submit an article please subscribe to our PL Intelligence service.

The opinions expressed in the articles published in this section do not necessarily reflect those of Pharmalicensing or UTEK Corporation. No actions including proposals to or agreements with other companies should be taken by any reader without obtaining specific business or legal advice. Neither the publisher nor the authors accept any liability for any actions or activities undertaken by any reader or other third party as a consequence of these articles or for any errors or omissions therein.